Femiguard

About

Funding history · 1 round · — total

Company Intelligence Q&A

Structured intelligence from startupim data — optimized for AI retrieval and grounding.

What is Femiguard's primary product?

Femiguard's primary product is the Feminity device, a retrievable fallopian tube occlusion device designed to block the ostium of the fallopian tube.

What medical conditions does Femiguard's Feminity device address?

The Feminity device by Femiguard offers a solution for infertile women diagnosed with hydrosalpinx and for women seeking reversible nonhormonal contraception.

What is the intended benefit of the Feminity device for women with hydrosalpinx?

The Feminity device is designed to prevent the spillage of undesired fluids into the uterine cavity, which is intended to increase IVF implantation rates for women with hydrosalpinx.

When was Femiguard founded?

Femiguard was founded in October 2020.

Where is Femiguard headquartered?

Femiguard is headquartered in Ra'anana, Israel.

Which investor participated in Femiguard's undisclosed funding round in November 2021?

Sanara Ventures was a lead investor in Femiguard's undisclosed funding round in November 2021.

What is Femiguard's current product stage?

Femiguard's product is currently in the clinical trial stage.

How many employees does Femiguard currently have?

Femiguard currently has 2 employees.

Who are the founders of Femiguard?

The founders of Femiguard are Tovy Sivan and Shlomi Cohen.

Sectors & technology

Tags